Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Udaya Kompella to Particle Size

This is a "connection" page, showing publications Udaya Kompella has written about Particle Size.

 
Connection Strength
 
 
 
1.654
 
  1. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008 Jan 29; 14:150-60.
    View in: PubMed
    Score: 0.273
  2. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005 Dec; 57(12):1555-63.
    View in: PubMed
    Score: 0.235
  3. Vooturi S, Bourne D, Panda JJ, Choi S, Kim H, Yandrapu SK, Kompella UB. Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):404-409.
    View in: PubMed
    Score: 0.162
  4. Damiati S, Scheberl A, Zayni S, Damiati SA, Schuster B, Kompella UB. Albumin-bound nanodiscs as delivery vehicle candidates: Development and characterization. Biophys Chem. 2019 08; 251:106178.
    View in: PubMed
    Score: 0.149
  5. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013 Dec 02; 10(12):4676-86.
    View in: PubMed
    Score: 0.102
  6. Rao VR, Upadhyay AK, Kompella UB. pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids. J Control Release. 2013 Nov 28; 172(1):341-350.
    View in: PubMed
    Score: 0.101
  7. Baid R, Upadhyay AK, Shinohara T, Kompella UB. Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein. J Biol Chem. 2013 Jun 14; 288(24):17372-83.
    View in: PubMed
    Score: 0.098
  8. Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013 Jun 28; 168(3):239-50.
    View in: PubMed
    Score: 0.098
  9. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012 Sep 25; 6(9):7595-606.
    View in: PubMed
    Score: 0.094
  10. Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol. 2005 Jul; 57(7):851-60.
    View in: PubMed
    Score: 0.057
  11. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005 Mar 28; 511(2-3):191-8.
    View in: PubMed
    Score: 0.056
  12. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res. 2004 Jul; 21(7):1119-26.
    View in: PubMed
    Score: 0.053
  13. Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res. 2004 Mar; 21(3):524-35.
    View in: PubMed
    Score: 0.052
  14. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol. 2003 Sep; 55(9):1199-206.
    View in: PubMed
    Score: 0.050
  15. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar; 44(3):1192-201.
    View in: PubMed
    Score: 0.049
  16. Clapp T, Munks MW, Trivedi R, Kompella UB, Braun LJ. Freeze-thaw stress of Alhydrogel ? alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen. Vaccine. 2014 Jun 24; 32(30):3765-71.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)